Methotrexate 1g/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free. Non-metastatic osteosarcoma in patients who have undergone surgical resection or ...

Methotrexate 25mg/mL; soln for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free. Non-metastatic osteosarcoma in patients who have undergone surgical resection or ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed warning ...

NEW YORK CITY -- Postoperative intravitreal methotrexate for retinal detachment led to a significant reduction in reoperation and improved visual acuity, a retrospective chart review showed. The ...

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease -- MIRROR randomized controlled trial ...

Please provide your email address to receive an email when new articles are posted on . Children with rheumatic diseases were shown to experience mild pain with subcutaneous injections of methotrexate ...

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the ...

A 57-year-old woman with BRAF-positive metastatic melanoma presented to the dermatology clinic for evaluation of rapidly growing nodules on her face and warty growths over her trunk and extremities 3 ...

LEXINGTON, Mass., August 28, 2025--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided ...

Methotrexate injection device approved The FDA has approved Otrexup for adults with active, severe rheumatoid arthritis or psoriasis who haven't responded first line therapy and children with active ...